Effect of Poractant Alfa Injection Combined with Non-invasive High Frequency Oscillatory Ventilation on Premature Infants with NRDS
Objective:To explore the effects of Poractant Alfa Injection combined with non-invasive high frequency oscillatory ventilation (HFOV) on pulmonary surfactant protein A (SP-A) and pulmonary circulatory function in premature infants with neonatal respiratory distress syndrome (NRDS).Method:A total of 120 premature infants with NRDS admitted to the Neonatology Department of Jiangxi Maternal and Child Health Hospital from March 2022 to February 2024 were selected and divided into control group and observation group by random number table method,with 60 cases in each group.On the basis of conventional treatment,the control group was treated with non-invasive HFOV,and the observation group was treated with Poractant Alfa Injection combined with non-invasive HFOV.The therapeutic effect,SP-A level,pulmonary circulatory function indexes[mean pulmonary artery pressure (MPAP),pulmonary vascular resistance (PVR) and extravascular lung water (EVLW)]before and after treatment of the two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P<0.05).After treatment,SP-A,MPAP,PVR and EVLW in two groups were lower than those before treatment,and those in observation group were lower than those in control group,the differences were statistically significant (P<0.05).Conclusion:Poractant Alfa Injection combined with non-invasive HFOV in the treatment of premature infants with NRDS can improve the curative effect,reduce the level of SP-A and improve the pulmonary circulation function,which has certain value.
Neonatal respiratory distress syndromeNon-invasive high frequency oscillation ventilationPoractant AlfaPulmonary surfactant protein APulmonary circulation function
万方数据
维普
